Palatin Technologies, Inc. Announces Fourth Quarter and Fiscal Year 2020 Financial Results and Provides a Business Update
– $82.9 Million in Cash and Cash Equivalents at June 30, 2020 – Mutual Termination of License Agreement with AMAG Pharmaceuticals for Vyleesi® in July 2020 Resulted in Palatin Receiving $12 Million from AMAG Plus $4.3 Million Due March 31, 2021 – Phase 2 Study Data of PL9643 for the Treatment of Dry Eye Disease …